UNC0064-12

CAS No. 1430089-64-7

UNC0064-12( UNC0064-12, UNC-0064-12, UNC 0064-12, UNC006412 )

Catalog No. M11817 CAS No. 1430089-64-7

2,4-Pyrimidinediamine with linker is a patent compound in WO2013055780A1.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 236 In Stock
5MG 235 In Stock
10MG 351 In Stock
25MG 591 In Stock
50MG 823 In Stock
100MG 1107 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    UNC0064-12
  • Note
    Research use only, not for human use.
  • Brief Description
    2,4-Pyrimidinediamine with linker is a patent compound in WO2013055780A1.
  • Description
    2,4-Pyrimidinediamine with linker is a patent compound in WO2013055780A1, Page 71; multikinase inhibitor and has a -NH2 terminal linker for further synthesis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    UNC0064-12, UNC-0064-12, UNC 0064-12, UNC006412
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    VEGFR
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1430089-64-7
  • Formula Weight
    364.45
  • Molecular Formula
    C19H24N8
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    NCCCNC1=CC=C(NC2=NC=CC(NC3=NNC(C4CC4)=C3)=N2)C=C1
  • Chemical Name
    N2-[4-[(3-Aminopropyl)amino]phenyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-2,4-pyrimidinediamine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.MULTIPLEXED KINASE INHIBITOR BEADS AND USES THEREOF. Patent Application WO/2013/055780 Kind Code: A1
molnova catalog
related products
  • Cabozantinib

    Cabozantinib (XL184, BMS-907351) is a potent multi-kinase inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50 of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

  • TG 100572 Hydrochlor...

    TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases.

  • Motesanib

    A potent, orally bioavailable, multikinase inhibitor inhibitor of VEGFR1/2/3, PDGFR and c-Kit with IC50 of 2-6 nM, 84 nM and 8 nM, respectively.